Returns Chart

Key Stats

Customize
Expense Ratio Total Assets Under Management Dividend Yield Turnover Ratio
0.76% 4.883B 1.07% 43.00%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized All Time Total Returns (Daily) Max Drawdown (All)
-169.20M 32.78% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
General
Security Type Mutual Fund
Oldest Share Symbol JNGLX
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Janus Henderson
Prospectus Benchmark Index
MSCI World/Health Care NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Andrew Acker 14.10 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 92
-169.20M
-4.628B Category Low
7.419B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of May 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of June 11, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
34.93%
8.42%
-12.27%
22.66%
4.41%
29.28%
25.60%
3.45%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
12.81%
25.42%
7.21%
-3.33%
23.36%
5.55%
21.97%
18.24%
9.35%
28.57%
12.71%
-8.94%
19.66%
1.21%
22.98%
12.67%
10.41%
29.23%
11.30%
-5.79%
25.15%
8.28%
25.64%
19.78%
6.24%
27.80%
8.60%
-14.73%
16.55%
6.29%
26.28%
13.35%
8.65%
As of June 11, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (6-11-21) 1.07%
30-Day SEC Yield (8-31-17) Upgrade
7-Day SEC Yield (12-18-12) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 26.03
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of March 31, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of March 31, 2021

Asset Allocation

As of March 31, 2021.
Type % Net % Long % Short
Cash 0.43% Upgrade Upgrade
Stock 92.12% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 7.45% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
UnitedHealth Group Inc 4.00% 398.93 0.26%
AstraZeneca PLC
3.87% -- --
AbbVie Inc 3.21% 115.70 0.24%
Merck & Co Inc 2.99% 75.45 -1.08%
Roche Holding AG
2.78% -- --
Novartis AG ADR 2.77% 93.60 0.98%
Humana Inc 2.56% 414.77 -1.05%
Abbott Laboratories 2.47% 110.48 0.52%
Boston Scientific Corp 2.46% 42.52 -0.91%
Vertex Pharmaceuticals Inc 2.31% 195.00 1.03%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee Upgrade
Administration Fee Upgrade
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio managers believe have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
General
Security Type Mutual Fund
Oldest Share Symbol JNGLX
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Janus Henderson
Prospectus Benchmark Index
MSCI World/Health Care NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Andrew Acker 14.10 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (6-11-21) 1.07%
30-Day SEC Yield (8-31-17) Upgrade
7-Day SEC Yield (12-18-12) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 26.03
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of March 31, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of March 31, 2021

Fund Details

Key Dates
Inception Date 7/6/2009
Last Annual Report Date 9/30/2020
Last Prospectus Date 1/28/2021
Share Classes
JAGLX Other
JFNAX A
JFNCX C
JFNNX N
JFNSX S
JNGLX D
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No